{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:55:40Z","timestamp":1773924940155,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ygyno.2018.06.015","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T23:59:50Z","timestamp":1529452790000},"page":"233-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Moving beyond \u201ccomplete surgical resection\u201d and \u201coptimal\u201d: Is low-volume residual disease another option for primary debulking surgery?"],"prefix":"10.1016","volume":"150","author":[{"given":"Beryl L.","family":"Manning-Geist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Hicks-Courant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison A.","family":"Gockley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela G.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitfield B.","family":"Growdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Michael J.","family":"Worley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2018.06.015_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.ygyno.2018.06.015_bb0010","first-page":"209","article-title":"The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer","volume":"51","author":"VT","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2018.06.015_bb0015","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl. Cancer Inst. Monogr."},{"issue":"9","key":"10.1016\/j.ygyno.2018.06.015_bb0020","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","article-title":"A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study","volume":"57","author":"Omura","year":"1986","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2018.06.015_bb0025","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2018.06.015_bb0030","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.015_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study","volume":"26","author":"Winter","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2018.06.015_bb0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.06.015_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2008.10.008","article-title":"Aggressive and complex surgery for advanced ovarian cancer: an economic analysis","volume":"112","author":"Aletti","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.015_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.015_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.015_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2006.03.028","article-title":"Splenectomy as part of cytoreductive surgery in ovarian cancer","volume":"102","author":"Magtibay","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.015_bb0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.015_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovarian, fallopian tube, and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.06.015_bb0075","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/IGC.0000000000000690","article-title":"Minimal macroscopic residual disease (0.1\u20131\u202fcm). Is it still a surgical goal in advanced ovarian cancer?","volume":"26","author":"Chiva","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.06.015_bb0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intrapertioneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"NEJM"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818309971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818309971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:42:30Z","timestamp":1758771750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818309971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0090825818309971"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving beyond \u201ccomplete surgical resection\u201d and \u201coptimal\u201d: Is low-volume residual disease another option for primary debulking surgery?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}